Novartis nets potential first-in-class medicine in new cardiovascular acquisition

Retrieved on: 2025-02-11 15:25:26

Tags for this article:

Click the tags to see associated articles and topics

Novartis nets potential first-in-class medicine in new cardiovascular acquisition. View article details on hiswai:

Excerpt

Anthos has been developing the monoclonal antibody abelacimab as a treatment to prevent stroke and systemic embolism in individuals with atrial ...

Article found on: www.europeanpharmaceuticalreview.com